Regulatory Affairs
Ireland Family Reunification 2026: The Complete Guide to Financial Thresholds, Waiting Periods, How to Apply, and What Every Sponsor Must Know
A detailed, practical guide to Ireland's Non-EEA Family Reunification Policy as updated in 2026. Covers the new financial thresholds for all sponsor categories, country-specific waiting periods, step-by-step application process, and a comprehensive pre-application checklist - essential reading for pharmacists, healthcare workers, and life science professionals bringing family to Ireland.
Regulatory Affairs
UK Looks to Spain’s "Catalonia Blueprint" to Boost Global Clinical Trials Competitiveness
As global competition intensifies, UK life sciences leaders are examining Spain’s thriving Catalonia region for strategies to attract commercial sponsors, streamline regulatory reviews, and revitalize Britain’s clinical trials sector.
Regulatory Affairs
Pharmaceutical Regulatory Update 2026: EU, UK, FDA & Global Changes Explained
A massive wave of regulatory reform is sweeping the global pharma industry in 2026. From the EU's most significant legislative overhaul in decades to the FDA's sweeping Operation TrialBlazer, we break down what quality, manufacturing, and regulatory teams need to know to stay compliant.
Regulatory Affairs
Eli Lilly Adapts Direct-to-Patient Model for UK Market with LillyDirect Launch
Eli Lilly has successfully brought its LillyDirect service to the UK. Adapted to comply with strict local regulations, the service partners with regulated healthcare organizations to offer secure, anti-counterfeit delivery of high-demand therapies like Mounjaro directly to patients' doors.
Industry
Galen’s Penthrox Inhaler Secures Expanded UK License for Paediatric Trauma Pain
Northern Ireland-based Galen has received an expanded UK license for its emergency pain relief inhaler, Penthrox (methoxyflurane). The self-administered "green whistle" is now officially approved for use in conscious children aged six and older suffering from trauma-associated pain.
Biotechnology
From Farming to Pharma: The History of Ireland’s Life Sciences Revolution
How did a nation once defined by agriculture and emigration transform into the world’s third-largest exporter of pharmaceuticals? We trace the deliberate policy shifts, educational reforms, and FDI strategies that built Ireland’s booming life sciences ecosystem.
Industry
Navigating Ireland’s Pharma Dependency: Strategies for Policy and Talent in an Uncertain Era
With pharmaceuticals making up 20% of Ireland’s GDP, the nation’s reliance on the industry brings immense economic benefit but notable risks. We explore how Ireland must adapt its policy, manage geopolitical headwinds, and aggressively attract skilled labour to secure its future.
Regulatory Affairs
Beyond the Headline: Are Irish Pharma Workers Truly the Highest Paid in Europe?
Recent reports suggest Irish pharma workers are the highest paid in Europe, but a deeper dive reveals a more complex reality. We analyze compensation packages, tax regimes, and cost of living across Europe’s top pharmaceutical hubs.
Industry
Egypt, Ireland Explore Industrial Cooperation in Pharmaceuticals, Renewable Energy, and Advanced Technologies
Egypt’s Minister of Industry and Ireland’s Ambassador discuss strategic collaboration across pharmaceuticals, renewable energy, and technology sectors, aiming to leverage Irish expertise for local manufacturing.
Clinical Trials
The 2026 Obesity Power Rankings: Which Pharma Giants Can Break the Lilly-Novo Duopoly?
With the obesity market projected to exceed $130 billion by 2034, we analyze the top 10 pharmaceutical companies vying for dominance. Explore our comprehensive Power Rankings assessing pipeline depth, clinical differentiation, and commercial infrastructure.
Industry
Viewpoint: Why Ireland’s Pharma Sector is Immune to the Global 'Carbon Leakage' Exodus
A new Central Bank of Ireland study reveals that while global manufacturers flee strict climate laws, Ireland's biopharma sector remains stubbornly rooted. Here is what this means for the future of Irish FDI.
Clinical Trials
Helus Pharma Secures US$50M Offering as MDD Trial Surpasses 86% Enrollment
Helus Pharma announces a $50 million offering to progress Phase 3 trials for their novel serotonergic agonists, alongside major clinical milestones and leadership updates.